Literature DB >> 21376538

Association between bovine casein antibody and new onset schizophrenia among US military personnel.

David W Niebuhr1, Yuanzhang Li, David N Cowan, Natalya S Weber, Jared A Fisher, Glen M Ford, Robert Yolken.   

Abstract

Schizophrenia is a pervasive neuropsychiatric disorder of uncertain etiology. Multiple studies have documented immune activation in individuals with schizophrenia. One antigen capable of inducing a prolonged immune response is bovine casein derived from ingested milk products. Increased levels of casein antibodies have been found in individuals with schizophrenia after diagnosis. This study was directed at determining the potential association between schizophrenia and pre-illness onset levels of immunoglobulin G (IgG) antibodies to bovine casein. Parallel analyses for casein antibody levels with bipolar disorder were included as comparison. Cases were service members who received medical discharges from the military with a schizophrenia diagnosis from 1992 to 2005. Serum specimens were selected for 855 cases and 1165 matched healthy controls. IgG antibodies to bovine whole-casein were measured by solid phase enzyme-linked immunosorbent assays (ELISAs). Hazard ratios (HR) were calculated to examine the associations of casein IgG level with risk of schizophrenia by time to diagnosis and by subjects' initial level. Increasing casein IgG antibody levels among those with a high initial level, drawn before diagnosis, was associated with an 18% increase in the hazard risk of schizophrenia per unit increase (value of low-positive standard) in IgG antibody levels (HR=1.18; 95% CI 1.04, 1.34). This is the first report to identify an association between the risk of schizophrenia and elevated antibodies to bovine casein prior to disease onset. Additional research is required to elucidate the complex genetic environmental interactions involved in the pathogenesis of schizophrenia and to identify potentially modifiable risk factors. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376538     DOI: 10.1016/j.schres.2011.02.005

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

1.  Monocyte activation detected prior to a diagnosis of schizophrenia in the US Military New Onset Psychosis Project (MNOPP).

Authors:  Natalya S Weber; Kristin L Gressitt; David N Cowan; David W Niebuhr; Robert H Yolken; Emily G Severance
Journal:  Schizophr Res       Date:  2018-01-06       Impact factor: 4.939

2.  Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Authors:  Deanna L. Kelly; Haley K. Demyanovich; Katrina M. Rodriguez; Daniela Ciháková; Monica V. Talor; Robert P. McMahon; Charles M. Richardson; Gopal Vyas; Heather A. Adams; Sharon M. August; Alessio Fasano; Nicola G. Cascella; Stephanie M. Feldman; Fang Liu; MacKenzie A. Sayer; Megan M. Powell; Heidi J. Wehring; Robert W. Buchanan; James M. Gold; William T. Carpenter; William W. Eaton
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

3.  Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia.

Authors:  Emily G Severance; Kristin L Gressitt; Meredith Halling; Cassie R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; Armin Alaedini; Didier Dupont; Faith B Dickerson; Robert H Yolken
Journal:  Neurobiol Dis       Date:  2012-07-16       Impact factor: 5.996

4.  Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder.

Authors:  Emily G Severance; Kristin L Gressitt; Shuojia Yang; Cassie R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; Armin Alaedini; Faith B Dickerson; Robert H Yolken
Journal:  Bipolar Disord       Date:  2013-12-06       Impact factor: 6.744

5.  Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.

Authors:  Emily G Severance; Kristin L Gressitt; Cassie R Stallings; Andrea E Origoni; Sunil Khushalani; F Markus Leweke; Faith B Dickerson; Robert H Yolken
Journal:  Schizophr Res       Date:  2013-06-06       Impact factor: 4.939

Review 6.  Gastroenterology issues in schizophrenia: why the gut matters.

Authors:  Emily G Severance; Emese Prandovszky; James Castiglione; Robert H Yolken
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

7.  Genome-wide genetic and transcriptomic investigation of variation in antibody response to dietary antigens.

Authors:  Rohina Rubicz; Robert Yolken; Armin Alaedini; Eugene Drigalenko; Jac C Charlesworth; Melanie A Carless; Emily G Severance; Bogdana Krivogorsky; Thomas D Dyer; Jack W Kent; Joanne E Curran; Matthew P Johnson; Shelley A Cole; Laura Almasy; Eric K Moses; John Blangero; Harald H H Göring
Journal:  Genet Epidemiol       Date:  2014-07       Impact factor: 2.135

Review 8.  Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling.

Authors:  Emily G Severance; Robert H Yolken; William W Eaton
Journal:  Schizophr Res       Date:  2014-07-15       Impact factor: 4.939

9.  IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia.

Authors:  Emily G Severance; Kristin L Gressitt; Armin Alaedini; Cathrin Rohleder; Frank Enning; J Malte Bumb; Juliane K Müller; Emanuel Schwarz; Robert H Yolken; F Markus Leweke
Journal:  Brain Behav Immun       Date:  2014-09-20       Impact factor: 7.217

10.  Biomarker identification and effect estimation on schizophrenia - a high dimensional data analysis.

Authors:  Yuanzhang Li; Robert Yolken; David N Cowan; Michael R Boivin; Tianqing Liu; David W Niebuhr
Journal:  Front Public Health       Date:  2015-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.